Jenny Horne dives into the latest quarterly figures from fast food giant McDonald's (MCD). She points to a revenue miss and breaks down the domestic versus international operations for the Golden Arches. Meanwhile, Jenny takes a look at Merck's (MRK) oncology drug strength as a key part of its post-earnings move.